Drug Profile
Research programme: protein-protein interaction inhibitors - HQL Pharmaceuticals
Alternative Names: BCL-2 inhibitors - HQL Pharmaceuticals; IAP inhibitors - HQL Pharmaceuticals; p53 inhibitors - HQL Pharmaceuticals; PPI inhibitors - HQL Pharmaceuticals; Protein-protein interaction inhibitors research programme - HQL Pharmaceuticals; Small molecule SMAC mimetics - HQL PharmaceuticalsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator HQL Pharmaceuticals
- Class Small molecules
- Mechanism of Action Apoptosis modulators; Inhibitor of apoptosis protein inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tumour suppressor protein p53 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Israel
- 19 Sep 2011 Early research in Cancer in Israel (unspecified route)